Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

Related AEGR
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Aegerion Pharmaceuticals Announces Resolution Of Warning Letter for JUXTAPID (lomitapide) Capsules

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $27.00 to $36.00.

Canaccord Genuity noted, “AEGR announced additional Juxtapid launch color, with the key takeaways being the $235K/$295K U.S. annual pricing (vs. our $250K estimate) for initiation/maintenance, respectively, and that >1,500 patients have been identified worldwide to date through the registry. As a result, we believe AEGR's goal of 250-300 patients on drug by YE13 and $15M - $25M FY13 revenue guidance (we model for $22M) could prove conservative. We have adjusted our model to account for the higher pricing and a slower 2013 ramp but increased revenue in 2014+.”

Aegerion Pharmaceuticals closed on Tuesday at $25.76.

Latest Ratings for AEGR

Aug 2014Deutsche BankMaintainsBuy
May 2014Goldman SachsInitiates Coverage onSell
May 2014Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (AEGR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional